Apollo Ingredients’ rapid financial revival and corporate reshuffle signal a bold reinvention in nutraceuticals

Small Indian listed company Apollo Ingredients reports a dramatic financial turnaround and management reshuffle as it accelerates its pivot into the nutraceutical ingredients market, raising questions about sustainability and transparency.

Apollo Ingredients’ claim to be building a nutraceutical ingredients platform comes after a more tangible development in the market: the BSE-listed company has reported a far stronger opening quarter for the 2026-27 financial year than anything described in the promotional release. For the quarter ended 30 June 2026, Apollo posted standalone revenue of ₹5.27 crore, operating profit of about ₹1.29 crore and net profit of ₹1.22 crore. Trendlyne’s compilation of BSE data shows that was a sharp step up from the March 2026 quarter, when revenue was ₹1.07 crore and net profit was ₹0.07 crore, while Moneycontrol put the year-on-year rise in sales at 835.85% and reported EBITDA of ₹1.30 crore. The board meeting to approve those unaudited numbers was held on 10 August 2026. (trendlyne.com)

Those quarterly figures followed an audited turnaround in the year to 31 March 2026. ScanX reported that Apollo Ingredients, formerly Indsoya, recorded total revenue of ₹503.20 lakh for FY26, up from ₹308.20 lakh a year earlier, while profit after tax rose to ₹70.85 lakh from ₹9.76 lakh and profit before tax increased to ₹95.36 lakh from ₹13.19 lakh. Total expenses were ₹407.84 lakh. ScanX said the board approved the audited standalone results on 15 May 2026 and that the company published the required newspaper notices in Active Times and Mumbai Lakshdeep on 17 May 2026. The same report said Apollo’s total assets had expanded to ₹722.02 lakh and paid-up share capital to ₹520 lakh. It also noted that a revised board outcome corrected the stated face value of the shares from ₹10 to ₹5, a change the company described as “purely clerical in nature”. (scanx.trade)

The statutory-style directors’ report carried by Goodreturns fills in several gaps left by the marketing-led narrative. It puts net sales or income from business operations at ₹49,024.24 thousand for FY26, with other income of ₹1,296.17 thousand, total expenses of ₹40,784.42 thousand and current tax of ₹2,450.75 thousand. It also shows no exceptional item and no deferred tax charge in that annual summary. Directors said they would not recommend a dividend for the year ended 31 March 2026 in order to conserve resources for future growth and expansion. Read against the June-quarter figures, that means Apollo’s revenue in the first three months of FY27 alone was already slightly higher than in the whole of FY26. (goodreturns.in)

The financial rebound has been accompanied by a recasting of the boardroom. Goodreturns and ScanX both say that, at the 15 May 2026 board meeting, James Mody ceased to be a non-executive director, Amol Dinkar Nigudkar was appointed an additional independent director, Kirit Ghanshyam Mutreja was redesignated managing director and Lovely Ghanshyam Mutreja moved from managing director to executive director, or marketing director, on terms including commission of up to 2% of sales instead of salary. Trendlyne’s record of BSE announcements shows those management changes resurfaced around the 46th AGM filings on 29 June 2026, alongside the voting results and other corporate updates. Whalesbook also linked the results announcement to wider corporate actions, including progress on a name-change process, and said the statutory auditors issued an unqualified opinion on the FY26 accounts. (goodreturns.in)

Not every public record appears to have caught up with that reshuffle. A The Company Check snapshot updated on 14 July 2026 still listed Lovely Ghanshyam Mutreja as managing director and Kirit Ghanshyam Mutreja as director, even though the May board decisions and the late-June AGM-era filings pointed to a different executive structure. For a small listed company trying to win credibility in a science-led health ingredients market, that lag matters: the same sequence of BSE disclosures tracked by Trendlyne shows Apollo was simultaneously dealing with AGM paperwork, trading-window restrictions and compliance filings for the June quarter. (thecompanycheck.com)

The listed vehicle behind the new wellness pitch is also much older than the branding suggests. The Company Check says Apollo Ingredients was incorporated on 24 October 1980 in Vasai, Maharashtra, is listed on BSE under code 503639 and had authorised capital of ₹10 crore and paid-up capital of ₹5.2 crore in its July 2026 snapshot. Trendlyne’s chronology indicates that shareholders approved an alteration to the object clause of the memorandum at the 29 June 2026 AGM, a sign that the company was still formalising the business shift behind its nutraceutical positioning. (thecompanycheck.com)

The market had already rewarded that burst of momentum, at least by mid-August. Moneycontrol said Apollo shares closed at ₹126.95 on 17 August 2026, having returned 1,150.74% over six months and 2,237.94% over 12 months. But the publicly available figures are not entirely neat. Moneycontrol’s results story said earnings per share rose to ₹1.17 from ₹2.70 a year earlier, while Trendlyne’s BSE table for the June 2026 quarter showed adjusted earnings per share of ₹1.17 against a loss of ₹0.10 in June 2025. That inconsistency does not alter the broad direction of travel, but it underlines why investors would be better served by the underlying filings than by simplified market rewrites. (moneycontrol.com)

For now, the clearest verified picture is of a very small listed business attempting a rapid reinvention. Its FY26 accounts were signed off with an unqualified audit opinion, directors chose to retain cash rather than pay a dividend, and the first quarter of FY27 was larger than the whole of the previous year on a revenue basis. Apollo’s public messaging talks about branded, science-backed ingredients; the harder test will be whether later filings show that the surge in sales can be sustained, and whether the company’s governance and disclosure trail becomes as consistent as its growth claims. (whalesbook.com)